Tim Russert’s death of an apparent heart attack at age 58 is a potent reminder of our vulnerability to the ravages of cardiovascular disease even in the face of major advances in understanding its causes and how to prevent its consequences. Tim Russert, ...
Hospital report cards have been around for more than 15 years to help consumers pick high quality centers and to motivate doctors and staff to improve their performance. Now a Canadian research team says the report cards are missing a major part of the ...
The third of three diabetes studies testing whether aggressively lowering blood sugar reduces risk of heart attacks and death from cardiovascular disease offers doctors and patients some clarity amid conflicting reports on the issue, the Los Angeles ...
Mayo Clinic researchers are weighing in on the troubled state of randomized clinical trials that are done to evaluate the safety and effectiveness of diabetes drugs. That focus on a stand-in measure of disease, or surrogate marker, makes trials faster, ...
Now that the campaigns of John McCain and Barack Obama have each released details of the candidates’ health records, the Health Blog decided to see how they match up when it comes to heart risk. Cardiologists typically assess a person’s risk of heart ...
Leave it to John McCain to revive the Vytorin controversy. McCain’s LDL (bad cholesterol) was about 83 on Vytorin, which is a combination pill that includes simvastatin with a second drug called Zetia. McCain was taking a dose of Vytorin that delivered ...
Boston Red Sox pitcher Jon Lester is a modest baseball hero. By all accounts, he’s an even more reluctant cancer-survivor. Both of those roles came into glorious celebration last night when the 24-year-old southpaw pitched a no-hitter against the ...
Researchers have long been puzzled by the fact that some of medicine’s most touted new cancer drugs work only 10% to 20% of the time against many common tumors. Now scientists at University of Texas M.D. Anderson Cancer Center in Houston have come up ...
WSJ’s blog on health and the business of health. Four years ago, Roger Newton was the envy of the pharmaceutical industry when Pfizer bought his startup biotech Esperion Therapeutics and a handful of experimental compounds that raised good ...
Will defenders of Merck’s and Schering-Plough’s beleaguered cholesterol drug Zetia find solace in a clinical trial called Sands? It’s possible because results appearing in the current issue of JAMA suggest that Zetia, also an ingredients in Vytorin, ...
Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.